Close

TraceLink and Advanco partner to simplify serialization line management integration

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

When to Bring in Outside Help for FDA Cybersecurity Compliance (and What to Look For)

Medical device cybersecurity has become too important to treat...

Billerud Introduces New Pharmaceutical Packaging Option

Billerud has officially introduced PharmaKraft, a specialized fibre-based packaging...

AstraZeneca Advances AI Drug Discovery Deal with insitro

AstraZeneca has inked a billion-dollar AI drug discovery partnership...
- Advertisement -

TraceLink Inc, the World’s Largest Track and Trace Network for connecting the Life Sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace.

Announced a partnership with Advanco to support pharmaceutical manufacturers with the integration of line management and enterprise systems when complying with new serialization regulations

The agreement will see TraceLink resell Advanco’s ARC® Suite software, an industry-leading software solution that integrates packaging lines and enterprise serialization repositories. It will allow pharmaceutical and contract manufacturing companies to utilize multiple line management systems, providing purchasing flexibility, while also simplifying integration with the TraceLink Life Sciences Cloud at the enterprise and network level for serialization.

As the leading provider for enterprise and network system Levels 4 and 5, TraceLink will offer the Advanco ARC Suite software to customers looking for a consistent global site server solution that is independent of the Line Management System (LMS). 

“Pharmaceutical and contract manufacturers continue to face a number of challenges in synchronizing multiple interconnected packaging levels in order to comply with serialization regulations. TraceLink and Advanco recognized the need to provide a flexible option for the industry to cut down on time-consuming and costly integrations between line management and enterprise systems and efficiently comply with serialization regulations,” said Shabbir Dahod, president and CEO of TraceLink.

“TraceLink is partnering with the industry’s leading companies, such as Advanco, to deliver flexible, scalable solutions, quality implementation services and proven production integrations to its customers. These partnerships supplement our ongoing and active involvement with interoperability standards and industry workgroups such as Open-SCS and GS1, which demonstrate TraceLink’s commitment to working collaboratively with industry to reduce risk and ensure optimal compliance for all members of the pharmaceutical supply chain.”

ARC Suite will streamline integration across all LMS solutions and remove any restrictions associated with purchasing from multiple line vendors resulting from implementing a proprietary site server. This simplified, interoperable approach through TraceLink and Advanco will allow manufacturers to leverage any combination of line management solutions, while improving procurement and deployment flexibility.

Olgun Yenersoy, founder and CEO of Advanco added: “TraceLink is the global leader in serialization and track and trace at the enterprise level because its proven Life Sciences Cloud serialization platform enables more than 500 pharmaceutical manufacturers, CMOs, distributors, 3PLs and dispensers to exchange data with over 248,000 supply chain partners. The TraceLink and Advanco integration offers true simplicity in system integration and will help facilitate smoother deployment of serialization solutions for all packaging levels. We look forward to this partnership with TraceLink and working collaboratively to help the industry achieve compliance in the EU, US and other global markets.”

Eric Tjoa, CEO of Tjoapack, commented: “As a customer of both TraceLink and Advanco, we’re able to offer easy integration across all line levels, well ahead of the US and EU deadlines, while continuing to guarantee the highest quality of services for our customer base. The partnership between TraceLink and Advanco gives us increased flexibility, particularly for our customers that need options for leveraging different line management strategies, ranging from a single system to several large line management systems. Seamless integration is a core component to success for serialization and an integral factor for pharmaceutical manufacturers to achieve compliance on time. 

“We are thrilled about this partnership and will be discussing the benefits of simplified line-level integration with both companies at our upcoming serialization event on March 30 at Tjoapack headquarters.”

In addition, customers who purchase ARC Suite by Advanco from TraceLink will be able to rely on TraceLink’s global customer success team for implementation assistance and ongoing technical support, further streamlining the user experience by coordinating support resources through TraceLink.

To learn more about TraceLink’s partnership with Advanco and ARC Suite, please visit www.tracelink.com

About Advanco
Founded in 1981, for the last 36 years Advanco has been working as a system integrator in diverse industry such as pharmaceutical, food, manufacturing, luxury goods, aeronautics, chemical and the automotive. Our experience in Pharma Packaging Serialization, starting with Turkish Track and Trace program, since 2009 is based on monitoring of supply chain events, traceability, and compliance with legislations that are vital for competitive advantage. Focused on the site execution management (Level 3) solution, the role of Advanco is to help its clients to be ready on time by harmonizing their businesses with existing/new regulations. Our mission is to contribute to continuously optimize the efficiency of the operations through “Serialized Plant Execution Management” for both production and distribution at the plant level.

About TraceLink
TraceLink is the World’s Largest Track and Trace Network for connecting the Life Sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace. Leading businesses trust the TraceLink Life Sciences Cloud to deliver complete global connectivity, visibility and traceability of pharmaceuticals from ingredient to patient. A single point and click connection to the Life Sciences Cloud creates a supply chain control tower that delivers the information, insight and collaboration needed to improve performance and reduce risk across global supply, manufacturing and distribution operations. A winner of numerous industry awards including Deloitte’s Technology Fast 500 (ranked number 149 in 2016), the Amazon AWS Global Start-Up Challenge Grand Prize, and the Edison Award for Innovation in Health Management, the Life Sciences Cloud is used by businesses across the globe to meet strategic goals in ensuring global compliance, fighting drug counterfeiting, improving on-time and in-full delivery, protecting product quality and reducing operational cost. For more information on TraceLink and our solutions, visit www.tracelink.com

 

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

When to Bring in Outside Help for FDA Cybersecurity Compliance (and What to Look For)

Medical device cybersecurity has become too important to treat...

Billerud Introduces New Pharmaceutical Packaging Option

Billerud has officially introduced PharmaKraft, a specialized fibre-based packaging...

AstraZeneca Advances AI Drug Discovery Deal with insitro

AstraZeneca has inked a billion-dollar AI drug discovery partnership...

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »